English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/216294
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:


Discovery and Optimization of a Compound Series Active against Trypanosoma cruzi, the Causative Agent of Chagas Disease

AuthorsHarrison, J.R.; Sarkar, S.; Hampton, S.; Riley, J.; Stojanovski, L.; Sahlberg, C.; Appelqvist, P.; Erath, J.; Mathan, V.; Rodriguez, A.; Kaiser, M.; González-Pacanowska, D.; Read, K.D.; Johansson, N.G.; Gilbert, I.H.
Issue Date2020
PublisherAmerican Chemical Society
CitationJournal of Medicinal Chemistry
AbstractChagas disease is caused by the protozoan parasite Trypanosoma cruzi. It is endemic in South and Central America and recently has been found in other parts of the world, due to migration of chronically infected patients. The current treatment for Chagas disease is not satisfactory, and there is a need for new treatments. In this work, we describe the optimization of a hit compound resulting from the phenotypic screen of a library of compounds against T. cruzi. The compound series was optimized to the level where it had satisfactory pharmacokinetics to allow an efficacy study in a mouse model of Chagas disease. We were able to demonstrate efficacy in this model, although further work is required to improve the potency and selectivity of this series.
Publisher version (URL)http://dx.doi.org/10.1021/acs.jmedchem.9b01852
Identifiersdoi: 10.1021/acs.jmedchem.9b01852
issn: 0022-2623
e-issn: 1520-4804
Appears in Collections:(IPBLN) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
Show full item record
Review this work

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.